Indegene targets EBITDA recovery in H2FY27
Indegene delivered strong Q1FY27 results with revenue rising 39.7% YoY to ₹10,631 million and PAT increasing 45.9% sequentially. Despite near-term margin pressure from strategic investments, management confirmed that EBITDA margins are on track to normalize to the 19-20% range by Q4FY27, driven by scaling Gen AI platforms and revenue recognition from large outcome-based contracts.
*this image is generated using AI for illustrative purposes only.
Indegene Limited reported consolidated revenue of ₹10,631 million ($112.5 million) for Q1FY27, a 39.7% year-on-year increase, while management reaffirmed its target to restore EBITDA margins to the historical 19–20% range by Q4FY27. The company’s active client base expanded to 105, with profit after tax (PAT) surging 45.9% sequentially to ₹1,162 million. This performance underscores strong operational leverage despite near-term margin pressure from strategic investments in go-to-market capabilities and large-scale Gen AI engagements.
The Board of Directors approved the unaudited financial results on July 30, 2026, in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Deloitte Haskins & Sells, the statutory auditor, issued an unmodified opinion on the interim financial information. During the subsequent earnings conference call on July 31, 2026, Chairman and CEO Manish Gupta and CFO Suhas Prabhu detailed the drivers behind the sequential growth and clarified the timeline for margin normalization.
Financial Performance
Indegene’s top-line growth was broad-based, with USD revenue rising 26.5% year-on-year. While net profit remained flat year-on-year at ₹1,162 million compared to ₹1,164 million in Q1FY25, it significantly outperformed the previous quarter’s ₹797 million. Employee benefits expense increased to ₹6,591 million from ₹4,815 million in Q1FY25, reflecting investments in headcount and compensation. Other income rose to ₹52 million from a loss of ₹17 million in the prior year period.
| Particulars | Q1FY27 (₹ million) | Q4FY26 (₹ million) | Q1FY25 (₹ million) |
|---|---|---|---|
| Revenue from operations | 10,631 | 10,034 | 7,608 |
| Total income | 10,921 | 10,142 | 7,829 |
| Total expenses | 9,394 | 8,888 | 6,308 |
| Profit before tax | 1,527 | 1,051 | 1,521 |
| Net profit | 1,162 | 797 | 1,164 |
| Basic EPS (₹) | 4.84 | 3.32 | 4.86 |
Margin Trajectory and Strategic Investments
Management attributed the sequential decline in adjusted EBITDA margins to two primary factors: one-time costs associated with workforce transformation and the initial cost carry of contracted Gen AI engagements under the Tectonic platform. Suhas Prabhu noted that these investments are expected to yield long-term efficiency gains. The company has adopted designated hedge accounting for forward contracts, which will mitigate the impact of forex volatility on reported margins going forward, although undesignated hedges remain material until December 2026.
What the Numbers Show
While revenue expanded by nearly 40% year-on-year, net profit remained flat against the prior year due to higher operating expenses, particularly employee benefits which rose by 36.9%. However, the 45.9% sequential jump in PAT indicates improving efficiency. The divergence between flat YoY PAT and robust revenue growth suggests that recent investments in talent and technology are currently absorbing margins, but the sequential improvement in EBITDA and PAT points to emerging operational leverage as the client base scales beyond the 100-active-client milestone. Management projects that revenue recognition from a major outcome-based omnichannel deal will begin in Q3FY27, with costs already incurred, thereby flowing directly to the bottom line and aiding margin recovery.
Client Concentration and Geography
Revenue concentration decreased slightly, with the top client contributing 9.0% of revenue compared to 12.4% in Q1FY25. The top five clients accounted for 30.4% of revenue, down from 37.9% in the same period last year. Geographically, North America remained the largest market, contributing 75.1% of revenue, followed by Europe at 22.2%. India contributed 0.5%, while the rest of the world accounted for 2.2%. The company’s Days Sales Outstanding (DSO) improved to 67 days from 71 days in Q1FY25, indicating better collection efficiency despite sequential growth.
Strategic Initiatives
Indegene highlighted its focus on GenAI offerings, noting that several solutions have moved from concept to revenue-generating engagements. The company aims to scale these capabilities through FY27, leveraging its homegrown platforms like the NEXT Unified Data Platform. With 29.0% of its delivery team possessing healthcare domain expertise, Indegene positions itself as an embedded revenue partner rather than a traditional IT service provider, aiming to capture higher-value work in commercial and medical activities.
Historical Stock Returns for Indegene
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +0.19% | -0.35% | +11.53% | +17.06% | -2.00% | -0.54% |
How will the transition of Gen AI engagements from cost centers to revenue-generating assets impact Indegene's EBITDA margin trajectory in Q3 and Q4 FY27?
What specific strategies is Indegene employing to mitigate the risk of forex volatility on reported margins until the undesignated hedges expire in December 2026?
Will the commencement of revenue recognition from the major outcome-based omnichannel deal in Q3FY27 be sufficient to offset any potential headwinds in new client acquisition?
20
Access Market Heat-map & Insights 
Create, Save & Share your Screener 
Use 200+ Screening Filters 
